|
|
|
|
|
Mometasone
drug data and news
Mometasone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Mometasone | ||
| Brand Names/Synonyms | Asmanex Twisthaler; Combisor; Elocom; Elocon; Mometasone; Mometasone Furoate; Nasonex | ||
| Indication | For the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older (as an inhalant). Also used as a cream/ointment for the relief of inflammatory and pruritic manifestations of dematoses. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g. mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (e.g. histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma and in skin lesions. | ||
| Mechanism Of Action | Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. | ||
| Mometasone News (When available) |
New Survey Shows Europeans' Allergy Symptoms Are Most Severe in ... Feb 14, 2006 Schering-Plough swings to profit in Q4 Jan 31, 2006 Montelukast (Singulair) Added to Antihistamine or Corticosteroid ... Nov 11, 2005 Once-Daily Asthma Inhaler Approved Nov 30, 2005 Data Show Nasal Congestion is Most Bothersome Symptom of Allergic ... Nov 8, 2005 Data Show Nasal Congestion is Most Bothersome Symptom of Allergic ... Nov 8, 2005 Schering-Plough To Webcast Presentation at Bear, Stearns 18th ... Sep 12, 2005 Nasal Sprays Sep 24, 2005 Research Shows Patients With Allergic Rhinitis Prefer NASONEX(R) ... Sep 6, 2005 FDA Approves Orally Disintegrating Prescription Antihistamine, Re ... Jul 23, 2005 Schering-Plough Expands Its Presence in Asia Pacific; Commercial ... Jul 6, 2005 NASONEX(R) (mometasone furoate monohydrate) Effective for Nasal ... Jun 29, 2005 NASONEX (mometasone furoate monohydrate) Effective for Nasal ... Jun 29, 2005 Schering-Plough Expands Its Presence in Asia Pacific; Commercial ... Jul 7, 2005 Changes in Inhaler Devices for Asthma And COPD Jun 19, 2005 Allergy medications: Know your options Jun 25, 2005 | ||
| Dosage Forms | CREAM; LOTION; METERED-DOSE (PUMP); OINTMENT | ||
| Drug_Category | Anti-allergic Agents; Anti-inflammatory Agents; ATC:D07AC13; ATC:D07XC03; | ||
| Absorption | Nasal spray is virtually undetectable in plasma | ||
| Interactions |
Interactions for Mometasone: In clinical studies, the concurrent administration of the ASMANEX® TWISTHALER® inhaler and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse events. However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing. | ||
| Toxicity | Symptoms of hypercorticism | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8, 11,12, | ||
| Chemical Formula | C22H28Cl2O4 | ||
| Molecular Weight | 427.361 g/mol | ||
| Smiles String | CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C | ||
| Melting Point | 218-220 °C | ||
| Water Solubility | Practically insoluble | ||
| State | Solid, white powder | ||
| LogP/Hphobicity | 3.052 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 5.8 hours | ||
| Protein Binding [%] | 98% to 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Mometasone.html http://www.rxlist.com/cgi/generic2/momet1.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00289 | ||
| CAS Registry Number | 105102-22-5 | ||
| KEGG Compound ID | C07816 | ||
| PubChem ID | SID:700342 | ||
| PharmGKB ID | PA450541 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2238465 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |